Graney & King LLC Makes New Investment in Novo Nordisk A/S (NYSE:NVO)

Graney & King LLC purchased a new position in Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, Holdings Channel reports. The fund purchased 607 shares of the company’s stock, valued at approximately $52,000.

Other large investors also recently made changes to their positions in the company. Victory Capital Management Inc. lifted its position in shares of Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company’s stock worth $5,410,000 after purchasing an additional 23,223 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after buying an additional 19,870 shares during the last quarter. Bryn Mawr Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 358.8% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after acquiring an additional 30,420 shares during the period. Versant Capital Management Inc acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter worth $86,000. Finally, Talbot Financial LLC bought a new position in Novo Nordisk A/S during the fourth quarter worth $4,066,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.5 %

NYSE NVO opened at $71.74 on Thursday. Novo Nordisk A/S has a 1-year low of $70.39 and a 1-year high of $148.15. The company has a market capitalization of $321.94 billion, a price-to-earnings ratio of 21.81, a PEG ratio of 0.90 and a beta of 0.42. The stock’s 50 day moving average is $82.78 and its two-hundred day moving average is $99.75. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 47.72%.

Analysts Set New Price Targets

Several research firms have issued reports on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 21st. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.